News

AveriSource Launches Advanced Platform with GenAI Integration

AveriSource Launches Advanced Platform with GenAI Integration

AveriSource Unveils Platform 3.0 with Innovative GenAI Solutions

AveriSource, a notable independent software vendor, recently introduced the latest version of its application modernization platform, known as AveriSource Platform™ 3.0. This enhanced platform integrates cutting-edge Generative AI (GenAI) capabilities, designed to significantly improve the efficiency and speed of mainframe and midrange application modernization processes. With the launch of Averi™, users can automate essential tasks including application analysis, documentation creation, and user story development, which ultimately leads to a more streamlined modernization journey.

Key Advancements in AveriSource Platform 3.0

AveriSource Platform 3.0 is a substantial upgrade, offering organizations the tools they need to modernize their legacy systems effectively. This platform's primary goal is to assist in transitioning to microservices and cloud-native architectures, which helps clients maximize the advantages of cloud computing. By making innovative use of AI and automation, it empowers businesses to accelerate modernization efforts that traditionally could take many months.

Enhanced Functionalities through GenAI

The integration of GenAI within the platform revolutionizes the modernization process. The new assistant, Averi, is crucial for simplifying the creation of application modernization assessments and business requirements documentation, making the overall process efficient and less time-consuming.

Core Features of AveriSource Platform 3.0

The platform introduces remarkable features aimed at boosting productivity and accuracy in modernization efforts. Here are some key functionalities:

  • Application Analysis: Conduct detailed analyses of legacy code bases without the need for manual intervention, enhancing both speed and accuracy.
  • Documentation Automation: The platform automates the generation of application documentation, streamlining project management during the modernization process.
  • User Story Generation: Effective creation of user stories aligns project development with business objectives, facilitating comprehensive project planning.

Introducing New Product Offerings

Averi for AveriSource Discover

With the new GenAI capabilities, Averi now efficiently generates assessment reports that offer insights on legacy architectures, dependencies, and possible enhancements. This is crucial for developing and executing successful modernization strategies.

Averi for AveriSource Analyze

Additionally, Averi automates the production of business requirements documentation (BRD), linking the analysis of legacy systems directly to business strategies while streamlining application rewrite plans.

Strategic Cloud and On-Prem LLM Integrations

The AveriSource Platform 3.0 has made significant strides by integrating with Amazon Bedrock, providing users with powerful large language model capabilities. This integration enhances documentation, analysis, and automation processes, ultimately leading to better project management.

On-Premises Solution: Meta Llama 3.1

For those concerned with data residency or compliance issues, the platform now supports Meta Llama 3.1 within an on-premises setting, ensuring that users can maintain data security while leveraging the advantages of GenAI technology.

Streamlined Code and Deployment Processes

AveriSource also announced enhancements to the AveriSource Transform module, significantly improving the path from code generation to deployment. This enhancement reduces time-to-market for modernization projects, ensuring that businesses can respond swiftly to changing needs.

Statements from Leadership

David Gutzman, CEO of AveriSource, expressed his enthusiasm for the latest release, stating, "We are excited to launch AveriSource Platform 3.0 and our focus on GenAI solutions that will support our partners and customers in their modernization projects. By lowering costs, reducing time, and mitigating risks associated with legacy applications, we are committed to transforming the modernization landscape on various platforms including cloud, mainframes, and midrange systems."

Availability of AveriSource Platform 3.0

AveriSource Platform 3.0 is now accessible through the AWS Marketplace and the AveriSource website. Those interested in learning more about the platform or scheduling a product demonstration can visit the official site for details.

About AveriSource

AveriSource is dedicated to redefining application modernization with innovative GenAI solutions. With three decades of experience in legacy application analysis and a robust knowledge base that has processed billions of lines of code, AveriSource offers a variety of modernization patterns and use cases. The company supports an extensive range of technology stacks and maintains a global network of partners and systems integrators, providing comprehensive solutions tailored to meet diverse strategies across mainframe, midrange, and cloud environments.

Frequently Asked Questions

What is AveriSource Platform 3.0?

AveriSource Platform 3.0 is the latest version of AveriSource's application modernization platform, integrating Generative AI capabilities for enhanced efficiency.

How does the GenAI assistant, Averi, contribute?

Averi automates vital tasks such as application analysis, documentation generation, and business requirement creation, speeding up the modernization process.

What are the main benefits of using the new platform?

The platform provides significant efficiency improvements, reduced modernization times, and enhanced accuracy through automation.

Can the platform integrate with existing systems?

Yes, AveriSource Platform 3.0 supports integration with numerous tech stacks, making it versatile for various legacy systems.

Where can I find more information about AveriSource?

For more details, you can visit the AveriSource website, where information about their products and offerings is available.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 183

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 742

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 437

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 209

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 221

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Marina Genova Joins SEA Index to Promote Sustainable Yachting

Updated Category News Views 173

Marina Genova Enters SEA Index as an Institutional Member Recently, the Superyacht Eco Association – SEA Index welcomed Marina Genova, a prominent destination for yachting in the Mediterranean, as an Institutional Member. This collaboration signifies a crucial step in the yachting community's commitment to integrating environmental sustainability into its operations....

Continue Reading
Warren Buffett’s Top 2025 Stock Picks You Need to Know

Updated Category News Views 2610

Warren Buffett’s Strategic Stock Investments for 2025 Warren Buffett, the Oracle of Omaha, is known for his keen investment strategies and ability to recognize value in both good and bad market conditions. In the current volatile landscape, his portfolio continues to evolve, with some old favorites and new bets that show his forward-thinking approach. As we look ahead...

Continue Reading
Graves' Ophthalmopathy Market Surges with New Therapies

Updated Category News Views 50

Unexpected Growth in Graves' Ophthalmopathy Market Over the next decade, we're seeing the Graves' ophthalmopathy market gearing up for some serious growth, clocking in at a hefty compound annual growth rate of 9%. A good chunk of this is thanks to Viridian's newest player, LUMVOA, getting the green light, sending competitors scrambling and pushing innovation into...

Continue Reading
Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution

Updated Category News Views 210

So back in 2024, Tris Pharma rolled out ONYDA™ XR—this liquid medication aimed at tackling ADHD in kids six and older. It was billed as a game changer, especially since the FDA gave it the green light. The desks were buzzing about this first-of-its-kind non-stimulant therapy, positioning it like a golden ticket for parents tired of conventional stimulants that might...

Continue Reading
JPMorgan Updates Price Target for W. P. Carey to $70

Updated Category News Views 242

JPMorgan Boosts W. P. Carey's Price Target Recently, JPMorgan has refreshed its price target for W. P. Carey & Co. (NYSE: WPC), raising it from $68.00 to $70.00, while retaining an Overweight rating on the stock. This adjustment comes ahead of the company’s third-quarter earnings announcement, indicating the firm's confidence in W. P. Carey’s future potential....

Continue Reading